Akhmal Yusof – CEO, Clinical Research Malaysia (CRM)
Dr Akhmal Yusof, CEO of CRM sheds light on the capacity for all stages of clinical research in Malaysia. He discusses the importance of human resources for the country’s research…
Clinical Research Malaysia (CRM) is a non-profit organization wholly owned by the Government of Malaysia. It was established in June 2012 to promote Malaysia as a preferred global destination for industry sponsored clinical research (ISR). CRM provides a range of services to enable and facilitate sponsors (primarily from the pharmaceutical and medical device industries) and contract research organizations (CROs) to initiate a wide spectrum of clinical trials in Malaysia.
CRM’s key functions encompasses three core components, the first of which is securing clinical trials. This is done through advertising and promotional activities, participation in key conferences, involvement in clinical trial distribution and strategic collaborations with major stakeholders. The second component involves closing the deals through a comprehensive feasibility study, convincing site review operation and implementation of an efficient financial, administration and approval process. The third component is conducting the trials. This is achieved through our high quality Study Coordinators and Principal Investigators, effective standard operating procedures, quality assurance of study sites and support services.
CRM Contact Details
Clinical Research Malaysia
Suite E-10-20, Amcorp Business Suites, Menara Melawangi,
Amcorp Trade Centre, No.18, Jalan Persiaran Barat,
46050 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
T: +603 7960 5153
F: +603 7932 1940
E: contact@clinicalresearch.my
W: www.clinicalresearch.my
Get connected socially,
facebook.com/clinicalresearchmalaysia
twitter.com/clinicalrsrchmy
youtube.com/ClinicalRsrchMy
linkedin.com/company/clinical-research-malaysia
Dr Akhmal Yusof, CEO of CRM sheds light on the capacity for all stages of clinical research in Malaysia. He discusses the importance of human resources for the country’s research…
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
Klinsel’s CEO discusses the company’s ambitions of growth in a very competitive CRO market and stresses that local experience is truly a distinguishing factor and this is why they are…
Novo Nordisk Malaysia’s general manager shares the ongoing fight to cure diabetes and talks about the necessity to raise awareness, with for instance their current MoU with the ministry of…
Malaysia Healthcare Travel Council’s CEO is proud of her country’s healthcare system and their efforts at attracting medical tourists from all over the world, with the support of the healthcare…
Mundipharma Malaysia’s country manager discusses his company’s aim to become a reference in Malaysia for pain management, on the back of the tremendous 48 percent growth of the business last year. …
Lundbeck’s country manager gives a thorough overview of CNS disorders in Malaysia and states: “It is important to remind everyone that mental health conditions or brain diseases are not to…
MMA’s president shares the reasons why Malaysia is ranked today third in terms of healthcare quality, with a very efficient public system, high quality doctors and strong government support. However,…
IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also…
Aspen Malaysia’s country manager details the company’s success in the country with a specific business model based on acquiring and remarketing originators. Although Aspen is a renowned generic player, market dynamics…
MGCC’s Executive Director discusses the opportunities and challenges for German pharma and healthcare companies to invest in Malaysia, at a time where most have decided to invest and base their…
See our Cookie Privacy Policy Here